Asia-Pacific Multiple Sclerosis Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Nov 2020
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 304
  • No of Figures: 45

Asia-Pacific Multiple Sclerosis Treatment Market, By Disease Type (Relapsing–Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing–Remitting Multiple Sclerosis (RES)), Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), Drug Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospital, Homecare, Specialty Centers, Others), Distribution Channel (Retail Sales, Direct Tender), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2027

Asia-Pacific Multiple Sclerosis Treatment MarketMarket Analysis and Insights : Asia-Pacific Multiple Sclerosis Treatment Market

The multiple sclerosis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.5% in the forecast period of 2020 to 2027 and is expected to reach USD 4,430.79 million by 2027. Extensive research and development activity in multiple sclerosis treatment, increasing prevalence of multiple sclerosis, increasing need for better multiple sclerosis treatment options are the major drivers which propelled the demand of the market in the forecast period.

Multiple sclerosis is a chronic, inflammatory, autoimmune disorder that affects the (CNS) central nervous system, especially the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating covers of nerve cells in the brain and spinal cord. There is usually no cure for MS, general care is based on speedy recovery from damage that delays disease progression and manages MS symptoms.

MS symptoms differ greatly and depend on the amount of damage to the nerves and the form and position of affected nerves. MS symptoms include numbness or weakness of limbs usually affecting one side of the body, partial or total loss of vision, double vision and feelings of electrical shock in some neck movements, tremor and lack of balance or erratic gait, slurred voice, nausea, dizziness, bowel and bladder issues among others. Extreme MS can affect walking ability independently or lead to total disability. The key causes of MS are problems with walking and balance, muscle weakness, fatigue, issues with vision but the symptoms of MS vary from patient to patient.

The rising number of patients, increased screening and the need for better care options are thought to be the key factors for the multiple sclerosis treatment market growth during the forecast period. In ageing population, the disease is more prone, hence the surge in the geriatric population further escalates the multiple sclerosis treatment market growth.

The multiple sclerosis treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the multiple sclerosis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Multiple Sclerosis Treatment MarketAsia-Pacific Multiple Sclerosis Treatment Market Scope and Market Size

The multiple sclerosis treatment market is segmented on the basis of disease type, treatment, drug type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the multiple sclerosis treatment market is segmented into relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS) and severe relapsing–remitting multiple sclerosis (RES). In 2020, relapsing–remitting multiple sclerosis (RRMS) segment is dominating the multiple sclerosis treatment market because relapsing–remitting multiple sclerosis (RRMS) has the highest prevalence rate. It is the most common form of multiple sclerosis at onset and accounts for about 85% of all cases.
  • On the basis of treatment, the multiple sclerosis treatment market is segmented into symptomatic therapies, abortive therapies/treatment of acute exacerbations and preventive therapies. In 2020, preventive therapies segment is dominating the multiple sclerosis treatment market because of high R&D expenditure by large companies and as the immune system eats away at the protective covering of nerves, prevention is highly sought after.
  • On the basis of drug type, the multiple sclerosis treatment market is segmented into branded and generic. In 2020, branded segment is dominating the multiple sclerosis treatment market because of large number of products which are being launched from time-to-time by several companies making it difficult for generics to take over the market.
  • On the basis of route of administration, the multiple sclerosis treatment market is segmented into oral and parenteral. In 2020, oral segment is dominating the multiple sclerosis treatment market because of the large number of medication available in oral dosage form which promotes patient satisfaction and increases therapeutic compliance.
  • On the basis of end user, the multiple sclerosis treatment market is segmented into hospital, specialty centers, homecare and others. In 2020, hospital segment is dominating the multiple sclerosis treatment market because hospitals are the primary place for the diagnosis and treatment of multiple sclerosis. Large number of patients visited the hospitals due to the presence of skilled professionals and advanced technology for the diagnosis.
  • On the basis of distribution channel, the multiple sclerosis treatment market is segmented into direct tender and retail sales. In 2020, retail sales segment is dominating the multiple sclerosis treatment market because of the large number of products available according to the patient requirement. Moreover, retail sales focus heavily on the costs associated with overhead and they provide instant gratification.

Multiple Sclerosis Treatment Market Country Level Analysis

The multiple sclerosis treatment market is analysed and market size information is provided by country, disease type, treatment, drug type, route of administration, end user and distribution channel as referenced above.

The countries covered in the multiple sclerosis treatment market report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific

Asia-Pacific is expected to grow with the fastest CAGR in the forecast period due to huge demand for multiple sclerosis treatment are increasing very rapidly due to increasing geriatric population and rising awareness regarding the treatment of multiple sclerosis. China is expected to dominate the market in Asia-Pacific due to changing lifestyle along with increasing prevalence of multiple sclerosis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Multiple Sclerosis Treatment Market

Multiple sclerosis treatment market also provides you with detailed market analysis for every country growth in particular industry with multiple sclerosis treatment sales, impact of advancement in the multiple sclerosis treatment and changes in regulatory scenarios with their support for the multiple sclerosis treatment market. The data is available for historic period 2010 to 2018

Competitive Landscape and Multiple Sclerosis Treatment Market Share Analysis

Multiple sclerosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to multiple sclerosis treatment market.

The major players covered in the report Genzyme Corporation (a subsidiary of Sanofi), Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), F. Hoffmann-La Roche Ltd, Merck KGaA, Mallinckrodt, Pfizer Inc., Hikma Pharmaceuticals PLC, Par Pharmaceutical (a subsidiary of Endo International plc), Mylan N.V., Novartis AG, Biogen, CELGENE CORPORATION (a subsidiary of Bristol-Myers Squibb Company), Lannett, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Bayer AG, Amneal Pharmaceuticals LLC and other global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the multiple sclerosis treatment market.

For instance,

  • In August 2020, Mylan N.V. launched the generic drug Dimethyl fumarate delayed release capsules 120 mg and 240 mg for the treatment of relapsing forms of multiple sclerosis (MS). The newly launched drug is therapeutically equivalent to the Biogen's Tecfidera capsules. This new FDA approved drug launched by the company during the COVID-19 pandemic has increased its credibility in the market
  • In June 2020, Bristol-Myers Squibb Company, a parent company of CELGENE CORPORATION announced that they have launched their new oral drug for a relapsing form of multiple sclerosis (MS) named ZEPOSIA (ozanimod). This new product launched by the company will increase its demand in the market in the future.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the multiple sclerosis treatment market which also provides the benefit for organisation to improve their offering for multiple sclerosis treatment.

Customization Available: Asia-Pacific Multiple Sclerosis Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE

TABLE 3 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 1 ASIA-PACIFIC RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 2 ASIA-PACIFIC SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 ASIA-PACIFIC PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 9 ASIA-PACIFIC INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 ASIA-PACIFIC INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 11 ASIA-PACIFIC GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 ASIA-PACIFIC ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 ASIA-PACIFIC ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 ASIA-PACIFIC CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 ASIA-PACIFIC SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 ASIA-PACIFIC SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 23 ASIA-PACIFIC BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 ASIA-PACIFIC BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 25 ASIA-PACIFIC GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 ASIA-PACIFIC ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 31 ASIA-PACIFIC HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 ASIA-PACIFIC HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 ASIA-PACIFIC SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 ASIA-PACIFIC OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 40 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 41 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 42 ASIA-PACIFICPREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 43 ASIA-PACIFICORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 44 ASIA-PACIFICINJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 45 ASIA-PACIFICINTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 46 ASIA-PACIFICGLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 47 ASIA-PACIFICINTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 48 ASIA-PACIFICINFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 49 ASIA-PACIFICABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 50 ASIA-PACIFICCORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 51 ASIA-PACIFICIMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 52 ASIA-PACIFICSYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 53 ASIA-PACIFICMUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 54 ASIA-PACIFICFATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 55 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 ASIA-PACIFIC BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 57 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 58 ASIA-PACIFIC PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 59 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 60 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 61 ASIA-PACIFIC RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 62 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 63 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 JAPAN PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 JAPAN ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 JAPAN INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 JAPAN INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 JAPAN GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 JAPAN INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 JAPAN INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 JAPAN ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 JAPAN CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 JAPAN IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 JAPAN SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 JAPAN MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 JAPAN FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 JAPAN BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 79 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 80 JAPAN PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 81 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 82 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 83 JAPAN RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 84 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 85 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 86 CHINA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 CHINA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 CHINA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 CHINA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 CHINA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 CHINA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 CHINA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 CHINA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 CHINA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 CHINA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 CHINA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 CHINA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 CHINA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 99 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 100 CHINA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 101 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 102 CHINA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 103 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 104 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 105 CHINA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 106 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 107 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 INDIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 109 INDIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 110 INDIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 111 INDIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 112 INDIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 113 INDIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 114 INDIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 INDIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 INDIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 INDIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 INDIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 INDIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 INDIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 122 INDIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 123 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 124 INDIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 126 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 127 INDIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 129 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 SOUTH KOREA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 SOUTH KOREA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 SOUTH KOREA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 SOUTH KOREA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 SOUTH KOREA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 SOUTH KOREA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 SOUTH KOREA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 137 SOUTH KOREA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 138 SOUTH KOREA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 139 SOUTH KOREA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 140 SOUTH KOREA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 141 SOUTH KOREA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 142 SOUTH KOREA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 143 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 SOUTH KOREA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 145 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 146 SOUTH KOREA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 147 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 148 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 149 SOUTH KOREA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 150 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 151 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 AUSTRALIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 AUSTRALIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 AUSTRALIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 AUSTRALIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 AUSTRALIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 AUSTRALIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 AUSTRALIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 AUSTRALIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 AUSTRALIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 AUSTRALIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 AUSTRALIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 AUSTRALIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 AUSTRALIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 165 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 166 AUSTRALIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 167 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 168 AUSTRALIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 169 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 170 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 171 AUSTRALIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 172 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 173 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 SINGAPORE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 SINGAPORE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 SINGAPORE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 SINGAPORE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 SINGAPORE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 SINGAPORE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 SINGAPORE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 SINGAPORE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 SINGAPORE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 SINGAPORE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 SINGAPORE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 SINGAPORE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 SINGAPORE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 187 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 188 SINGAPORE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 189 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 190 SINGAPORE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 191 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 192 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 193 SINGAPORE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 194 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 195 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 196 MALAYSIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 197 MALAYSIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 198 MALAYSIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 199 MALAYSIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 200 MALAYSIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 201 MALAYSIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 202 MALAYSIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 203 MALAYSIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 204 MALAYSIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 205 MALAYSIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 206 MALAYSIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 207 MALAYSIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 208 MALAYSIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 209 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 210 MALAYSIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 211 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 212 MALAYSIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 213 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 214 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 215 MALAYSIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 216 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 217 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 218 THAILAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 219 THAILAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 220 THAILAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 221 THAILAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 222 THAILAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 223 THAILAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 224 THAILAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 225 THAILAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 226 THAILAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 227 THAILAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 228 THAILAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 229 THAILAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 230 THAILAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 231 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 232 THAILAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 233 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 234 THAILAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 235 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 236 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 237 THAILAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 238 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 239 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 240 INDONESIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 241 INDONESIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 242 INDONESIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 243 INDONESIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 244 INDONESIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 245 INDONESIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 246 INDONESIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 247 INDONESIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 248 INDONESIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 249 INDONESIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 250 INDONESIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 251 INDONESIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 252 INDONESIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 253 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 254 INDONESIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 255 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 256 INDONESIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 257 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 258 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 259 INDONESIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 260 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 261 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 262 PHILIPPINES PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 263 PHILIPPINES ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 264 PHILIPPINES INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 265 PHILIPPINES INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 266 PHILIPPINES GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 267 PHILIPPINES INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 268 PHILIPPINES INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 269 PHILIPPINES ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 270 PHILIPPINES CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 271 PHILIPPINES IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 272 PHILIPPINES SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 273 PHILIPPINES MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 274 PHILIPPINES FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 275 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 276 PHILIPPINES BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 277 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 278 PHILIPPINES PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 279 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 280 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 281 PHILIPPINES RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 282 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 283 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 284 VIETNAM PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 285 VIETNAM ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 286 VIETNAM INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 287 VIETNAM INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 288 VIETNAM GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 289 VIETNAM INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 290 VIETNAM INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 291 VIETNAM ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 292 VIETNAM CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 293 VIETNAM IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 294 VIETNAM SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 295 VIETNAM MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 296 VIETNAM FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 297 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 298 VIETNAM BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 299 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 300 VIETNAM PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 301 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 302 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 303 VIETNAM RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 304 REST OF ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions